M Partners reaffirmed their buy rating on shares of Trulieve Cannabis (OTCMKTS:TCNNF) in a research report sent to investors on Tuesday morning, Analyst Ratings Network reports. M Partners currently has a $31.00 target price on the stock.
Several other research analysts also recently commented on TCNNF. Stifel Nicolaus started coverage on shares of Trulieve Cannabis in a report on Wednesday, July 22nd. They issued a buy rating on the stock. Needham & Company LLC raised their price target on shares of Trulieve Cannabis from $18.20 to $29.25 and gave the stock a buy rating in a research report on Tuesday, August 4th. Cantor Fitzgerald raised their price target on shares of Trulieve Cannabis from $59.00 to $60.00 and gave the stock an overweight rating in a research report on Thursday, September 17th. Canaccord Genuity raised their price target on shares of Trulieve Cannabis from $45.00 to $51.00 and gave the stock a buy rating in a research report on Tuesday, September 22nd. Finally, Alliance Global Partners started coverage on shares of Trulieve Cannabis in a research report on Friday, September 25th. They issued a buy rating on the stock. Nine analysts have rated the stock with a buy rating, The company presently has an average rating of Buy and an average price target of $33.04.
Shares of TCNNF opened at $23.40 on Tuesday. Trulieve Cannabis has a one year low of $5.74 and a one year high of $26.50. The company’s fifty day moving average price is $20.44 and its 200 day moving average price is $16.02.
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, and Connecticut, as well as directly to patients through home delivery.
Featured Story: VIX – Volatility Index
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.